Meridian Bioscience (VIVO) Prelim. Q3 Revenue Misses Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Meridian Bioscience (VIVO) to Resume Trading at 7:45 a.m.
July 7, 2022 7:26 AM EDTMeridian Bioscience (NASDAQ: VIVO) to Resume Trading at 7:45 a.m.
... MoreMeridian Bioscience (VIVO) to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction, $34 Per Share
July 7, 2022 7:18 AM EDTMeridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. (KOSE: A137310) and SJL Partners LLC announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an all-cash transaction valued at approximately $1.53 billion.
Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before the Consortium's first offer before... More
Meridian Bioscience (VIVO) Halted, News Pending
July 7, 2022 7:03 AM EDTMeridian Bioscience (NASDAQ: VIVO) Halted, News Pending
... More


